Provided by Tiger Trade Technology Pte. Ltd.

Agenus

7.99
+0.38004.99%
Pre-market: 8.050.0600+0.75%08:20 EDT
Volume:676.56K
Turnover:5.31M
Market Cap:359.71M
PE:3.20
High:8.00
Open:7.56
Low:7.54
Close:7.61
52wk High:8.85
52wk Low:2.71
Shares:45.02M
Float Shares:42.21M
Volume Ratio:0.80
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.50
EPS(LYR):-0.0034
ROE:-1278.83%
ROA:12.53%
PB:-1.81
PE(LYR):-2,352.77

Loading ...

Agenus announces strategic prioritization of neoadjuvant BOT+BAL

TIPRANKS
·
Jul 14

Agenus Secures Strategic Financing to Advance Colon Cancer Program

TIPRANKS
·
Jul 13

U.S. Stocks on the Move-american Express, Deckers, Q32 Bio

Reuters
·
Jul 13

Agenus Signs Deal to Sell Up to $340 Million Worth of Securities; Shares Up Pre-Bell

MT Newswires Live
·
Jul 13

Agenus Secures up to $340 Mln to Advance Colon Cancer Drug into Late-stage Study; Shares Jump

Reuters
·
Jul 13

Agenus Issues Series A, Series B Warrants in USD 85 Million Private Placement

Reuters
·
Jul 13

Agenus - to Increase Board to Nine, Adding Two Directors Designated by Commodore Capital Master Lp

THOMSON REUTERS
·
Jul 13

Agenus Announces Oversubscribed Private Placement of up to $340 Million to Advance Registrational Robbin Trial of Neoadjuvant Bot+bal in Mss Colon Cancer

THOMSON REUTERS
·
Jul 13

Agenus - Discontinues Financial Support for Battman Phase 3 Study

THOMSON REUTERS
·
Jul 13

Agenus Issues 56,525 New Warrants, Sets SEC Resale Registration Deadline Within 90 Days

Reuters
·
Jul 07

Agenus' Potential Colorectal Cancer Combination Shows 21.2-Month Survival

MT Newswires Live
·
Jul 06

Agenus Reports Landmark Bot+bal Data Showing 33% Three-year Overall Survival in Refractory Mss Metastatic Colorectal Cancer Without Active Liver Metastases at Esmo Gi 2026

THOMSON REUTERS
·
Jul 06

Agenus to Present Three-year Survival Data from Bot+bal Phase 1b Study in MSS Metastatic Colorectal Cancer at ESMO GI 2026

Reuters
·
Jun 25

Agenus Shareholders Approve Governance, Compensation and Auditors

TIPRANKS
·
Jun 23

Agenus shareholders approve 5 million-share increase to 2019 equity plan at annual meeting

Reuters
·
Jun 23

Agenus Nears Key Readout as Botensilimab Pancreatic Cancer Trial Reaches Completion

TIPRANKS
·
Jun 12

Agenus announces virtual annual shareholders meeting

Reuters
·
Jun 03

Backlash over Trump's $1.776 billion fund tests Blanche's bid for US attorney general

Reuters
·
May 29

Agenus reports Phase 2 BOT+BAL melanoma trial shows 22% response rate

Reuters
·
May 22

Agenus says AI model predicts BOT+BAL response, survival in MSS metastatic colorectal cancer

Reuters
·
May 22